Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

Inclusion criteria :

• The participant has confirmed acid alpha-glucosidase (GAA) enzyme deficiency from anytissue source and/or 2 confirmed GAA gene mutations.
• The participant must provide signed, informed consent prior to performing any studyrelated procedures. Consent of a legally authorized guardian(s) is (are) required forlegally minor participant as defined by local regulation. If the participant islegally minor, signed written consent shall be obtained from parent(s)/legal guardianand assent obtained from participants, if applicable.

Exclusion criteria:

• The participant is <3 years of age.
• The participant has known Pompe specific cardiac hypertrophy.
• The participant is wheelchair dependent.
• The participant is not able to ambulate 40 meters (approximately 130 feet) withoutstopping and without an assistive device.
• The participant requires invasive-ventilation (non-invasive ventilation is allowed).
• The participant is not able to successfully perform repeated forced vital capacity (FVC) measurements in upright position of greater than or equal to 30% predicted andless than or equal to 85% predicted.
• The participant (and participant's legal guardian if participant is legally minor asdefined by local regulation) is (are) not able to comply with the clinical protocol.
• The participant has had previous treatment with alglucosidase alfa or anyinvestigational therapy for Pompe disease.
• The participant has prior or current use of immune tolerance induction therapy.
• The participant, if female and of childbearing potential, has a positive pregnancytest (beta-human chorionic gonadotropin) at baseline. The above information is not intended to contain all considerations relevant to aparticipant's potential participation in a clinical trial.